Gregory Ferenstein
Gregory Ferenstein is a senior fellow in drug policy at Reason Foundation.
-
Why is Texas investigating Meta’s AI Studio for offering unlicensed therapy?
Texas Attorney General Ken Paxton launched an investigation into Meta’s Artificial Intelligence Studio to determine whether its chatbot platform misleads children.
-
Nevada’s ban on AI therapists highlights regulation based on fear rather than analysis
This legislative approach could stifle innovation, prevent change and improvement in products and services, and harm the residents of Nevada.
-
FAQ: Timeline for FDA ibogaine approval
It can take between 5 and 12 years to complete a drug trial, but the timeline to drug approval can vary significantly depending on the type of treatment.
-
New York’s stalled AI bill would have blurred the line between disclosure and restriction
While pitched as a transparency measure, Assembly Bill 8595 would have set a new, unusually high bar for compliance.
-
Democrats pivot on AI: Less regulation, more redistribution
The focus of Sen. Mark Kelly’s “AI for America” plan departs from other federal artificial intelligence policy proposals introduced by Democrats.
-
Sen. Ted Cruz proposes federal regulatory sandbox to encourage AI innovation, development
The SANDBOX Act would allow innovators to obtain temporary regulatory waivers for artificial intelligence technologies from federal agencies.
-
A look at the White House’s pro-innovation artificial intelligence ‘action plan’
The White House's AI action plan represents a clear policy direction favoring rapid innovation and reduced regulatory oversight.
-
Psychedelics Policy Newsletter: DEA considers rescheduling psilocybin, FDA releases rejection decision, and more
Plus: Reason Foundation testifies in Mississippi, author Joe Dolce talks about his new psychedelics book, and more.
-
State psychedelics legalization and policy roundup — October 2025
Kentucky debates clinical ibogaine trials, Mississippi considers ibogaine, Massachusetts bill would decriminalize psilocybin, and more.
-
Colorado can lead on AI fairness without a regulatory straitjacket
There are evidence-based, market-oriented steps Colorado lawmakers could take in place of the state's existing artificial intelligence law.
-
Next steps after the Senate rejected an AI regulation moratorium
The Senate's compromise effort for a federal moratorium on state laws regulating AI may show the way toward a politically viable path.
-
Psychedelics Policy Newsletter: RFK Jr. gives hopeful approval timeline, Arizona advances ibogaine, and more
Plus: Former Texas Gov. Rick Perry on his strong commitment to advancing ibogaine as a treatment.
-
State psychedelics legalization and policy roundup — August 2025
Arizona allocates funding for ibogaine research, Reason Foundation to testify at Mississippi informational hearing about ibogaine, and more.
-
Existing laws already fight AI housing discrimination—new state AI bills increase confusion
Misguided artificial intelligence regulatory efforts risk limiting innovation and sowing misunderstanding in many markets.
-
Vermont attempts to regulate political AI deepfakes
Vermont lawmakers have introduced Senate Bill S.23, a proposal aimed at curbing the use of AI-generated synthetic media in state elections.
-
New York’s RAISE Act expands executive power over AI at the expense of legislative oversight
New York is the latest in a growing number of states attempting to regulate artificial intelligence.
-
Congress, states explore AI tools to fight Medicare, Medicaid fraud
Continued investment in artificial intelligence may help agencies achieve more accurate oversight and reduce waste in public health care spending.
-
Psychedelics Policy Newsletter: FDA prioritizes drug reform for psychedelics, Texas advances ibogaine research, and more
Plus: New psychedelics-related hire at the Department of Health and Human Services, update on state progress, and more.
